Copyright: © 2019 Elsevier Ltd. All rights reserved.

DelveInsight's Pompe Disease pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline ...

No writing assistance was utilized in the production of this manuscript. Methotrexate (MTX) is the widely agreed upon first-choice second-line agent to treat juvenile idiopathic arthritis (JIA ...

Read more here. While the usual suspects in affordable fashion are always churning out options, true fashion insiders know that some of the best pieces can actually be found at smaller, local labels.

In the CheckMate 274 study, adjuvant nivolumab demonstrated a significant improvement in disease-free survival (DFS) and showed a trend toward improved overall survival (OS) in an unselected ...

OBJECTIVES To determine whether continued methotrexate treatment increases the risk of postoperative infections or of surgical complications in patients with rheumatoid arthritis (RA) within one year ...

The FDA has expanded the interchangeable designation for Yuflyma (adalimumab-aaty), a biosimilar to Humira, to include all presentations.

Objective To evaluate the efficacy and safety of the Janus kinase-1-preferential inhibitor filgotinib versus placebo or tumour necrosis factor-α inhibitor therapy in patients with active rheumatoid ...

Guidelines have been compiled by The Joint Tuberculosis Committee of the British Thoracic Society to quantify the risks of reactivation of tuberculosis with anti-tumour necrosis factor α (anti-TNF-α) ...